Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.281 USD | +0.21% | -5.53% | +12.36% |
May. 14 | Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 02 | Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza as Chief Medical Officer | CI |
Financials (USD)
Sales 2024 * | 267K | Sales 2025 * | 267K | Capitalization | 28.68M |
---|---|---|---|---|---|
Net income 2024 * | -17M | Net income 2025 * | -22M | EV / Sales 2024 * | 108 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 108 x |
P/E ratio 2024 * |
-2
x | P/E ratio 2025 * |
-3.44
x | Employees | 7 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.81% |
Latest transcript on Aprea Therapeutics, Inc.
1 day | +0.21% | ||
1 week | -5.53% | ||
Current month | +3.55% | ||
1 month | -1.29% | ||
3 months | -15.91% | ||
6 months | +40.96% | ||
Current year | +12.36% |
Managers | Title | Age | Since |
---|---|---|---|
Oren Gilad
CEO | Chief Executive Officer | 56 | 22-04-30 |
John Hamill
DFI | Director of Finance/CFO | 60 | 23-01-29 |
Zeev Weiss
PRN | Corporate Officer/Principal | 62 | 22-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | 14-12-31 |
John Henneman
BRD | Director/Board Member | 62 | 19-07-31 |
Rifat Pamukcu
BRD | Director/Board Member | 66 | 22-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 5.281 | +0.21% | 2,543 |
24-05-17 | 5.27 | -5.72% | 8,153 |
24-05-16 | 5.59 | -3.62% | 14,751 |
24-05-15 | 5.8 | -1.53% | 11,445 |
24-05-14 | 5.89 | +5.37% | 8,820 |
Delayed Quote Nasdaq, May 20, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.36% | 28.62M | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- APRE Stock